Mahesh Gokara

Dr. Mahesh Gokara

Cancer Biology, Mayo Clinic, Jacksonville, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2010 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
BSBabu Sudhamalla
Babu Sudhamalla
Mahesh GokaraMahesh Gokara
Mahesh Gokara
NANavjeet Ahalawat
Navjeet Ahalawat
DADamu G. Amooru
Damu G. Amooru
RSRajagopal Subramanyam
Rajagopal Subramanyam

5 February 2010 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
SNSatyabala Neelam
Satyabala Neelam
Mahesh GokaraMahesh Gokara
Mahesh Gokara
BSBabu Sudhamalla
Babu Sudhamalla
DADamu G. Amooru
Damu G. Amooru
RSRajagopal Subramanyam
Rajagopal Subramanyam

21 February 2014 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DYDaniel Pushparaju Yeggoni
Daniel Pushparaju Yeggoni
Mahesh GokaraMahesh Gokara
Mahesh Gokara
DMDarla Mark Manidhar
Darla Mark Manidhar
ARAparna Rachamallu
Aparna Rachamallu
SNSailaja Nakka
Sailaja Nakka
RSRajagopal Subramanyam
Rajagopal Subramanyam

21 January 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Mahesh GokaraMahesh Gokara
Mahesh Gokara
BSBabu Sudhamalla
Babu Sudhamalla
DADamu G. Amooru
Damu G. Amooru
RSRajagopal Subramanyam
Rajagopal Subramanyam
Human serum albumin (HSA) is the most abundant protein in blood plasma, having high affinity binding sites for several endogenous and exogenous compounds. Trimethoxy flavone (TMF) is a naturally occurring flavone isolated from Andrographis viscosula and used in the treatment of dyspepsia, influenza, malaria, respiratory functions and as an astringent and antidote for poisonous stings of some insects. The main aim of the experiment was to examine the interaction between TMF and HSA at physiological conditions. Upon addition of TMF to HSA, the fluorescence emission was quenched and the binding constant of TMF with HSA was found to be KTMF = 1.0±0.01×103 M−1, which corresponds to −5.4 kcal M−1 of free energy. Micro-TOF Q mass spectrometry results showed a mass increase of from 66,513 Da (free HSA) to 66,823 Da (HAS +Drug), indicating the strong binding of TMF with HSA resulting in decrease of fluorescence. The HSA conformation was altered upon binding of TMF to HSA with decrease in α-helix and an increase in β-sheets and random coils suggesting partial unfolding of protein secondary structure. Molecular docking experiments found that TMF binds strongly with HSA at IIIA domain of hydrophobic pocket with hydrogen bond and hydrophobic interactions. Among which two hydrogen bonds are formed between O (19) of TMF to Arg 410, Tyr 411 and another one from O (7) of TMF to Asn 391, with bond distance of 2.1 Å, 3.6 Å and 2.6 Å, respectively. In view of the evidence presented, it is imperative to assign a greater role of HSA's as a carrier molecule for many drugs to understand the interactions of HSA with TMF will be pivotal in the design of new TMF-inspired drugs.

28 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGArchit Garg
Archit Garg
DMDarla Mark Manidhar
Darla Mark Manidhar
Mahesh GokaraMahesh Gokara
Mahesh Gokara
CMChandramouli Malleda
Chandramouli Malleda
CRCirandur Suresh Reddy
Cirandur Suresh Reddy
RSRajagopal Subramanyam
Rajagopal Subramanyam
Coumarin is a benzopyrone which is widely used as an anti-coagulant, anti-oxidant, anti-cancer and also to cure arthritis, herpes, asthma and inflammation. Here, we studied the binding of synthesized coumarin derivatives with human serum albumin (HSA) at physiological pH 7.2 by using fluorescence spectroscopy, circular dichroism spectroscopy, molecular docking and molecular dynamics simulation studies. By addition of coumarin derivatives to HSA the maximum fluorescence intensity was reduced due to quenching of intrinsic fluorescence upon binding of coumarin derivatives to HSA. The binding constant and free energy were found to be 1.957±0.01×105 M−1, −7.175 Kcal M−1 for coumarin derivative (CD) enamide; 0.837±0.01×105 M−1, −6.685 Kcal M−1 for coumarin derivative (CD) enoate, and 0.606±0.01×105 M−1, −6.49 Kcal M−1 for coumarin derivative methylprop (CDM) enamide. The CD spectroscopy showed that the protein secondary structure was partially unfolded upon binding of coumarin derivatives. Further, the molecular docking studies showed that coumarin derivatives were binding to HSA at sub-domain IB with the hydrophobic interactions and also with hydrogen bond interactions. Additionally, the molecular dynamics simulations studies contributed in understanding the stability of protein-drug complex system in the aqueous solution and the conformational changes in HSA upon binding of coumarin derivatives. This study will provide insights into designing of the new inspired coumarin derivatives as therapeutic agents against many life threatening diseases.

4 May 2009 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
RSRajagopal Subramanyam
Rajagopal Subramanyam
Mahesh GokaraMahesh Gokara
Mahesh Gokara
BSBabu Sudhamalla
Babu Sudhamalla
EREswarreddy Reddeem
Eswarreddy Reddeem
AGAnilkishor Gollapudi
Anilkishor Gollapudi
DADamu G. Amooru
Damu G. Amooru